journal article·2024-05-07

Tabletized Nanomedicine: From the Current Scenario to Developing Future Medicine

Rahul Tiwari, Meghana Kolli, Sumeet Chauhan, Murali M. Yallapu

ACS Nano· Volume 18· Issue 18
Publisher page

Abstract

The limitations of conventional therapeutic treatments prevailed in the development of nanotechnology-based medical formulations, termed nanomedicine. Nanomedicine is an advanced medicine that often consists of therapeutic agent(s) embedded in biodegradable or biocompatible nanomaterial-based formulations. Among nanomedicine approaches, tablet (oral) nanomedicine is still under development. In tabletized nanomedicine, the dynamic interplay between nanoformulations and the intricate milieu of the gastrointestinal tract simulates a pivotal role, particularly accentuating the influence exerted upon the luminal, mucosal, and epithelial cells. In this work, we document the perspectives and opportunities of nanoformulations toward the development of tabletized nanomedicine. This review also unveils the notion of integrating nanomedicine within a tablet formulation, which facilitates the controlled release of drugs, biomolecules, and agent(s) from the formulation to achieve a better therapeutic response. Finally, an attempt was made to explore current trends in nanomedicine technology such as bacteriophage, probiotic, and oligonucleotide tabletized nanomedicine and the combination of nanomedicine with imaging agents, i.e., nanotheranostics.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, United States

South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, Texas 78504, United States

Department of Biology, College of Science, University of Texas Rio Grande Valley, Edinburg, Texas 78539, United States

Funding

National Cancer Institute · Cancer Prevention and Research Institute of Texas · National Institute of General Medical Sciences

References (100+)

Show source-provided references
1. 10.1002/adma.20207009910.1002/adma.202070099 ↗
2. 10.1126/sciadv.abk179210.1126/sciadv.abk1792 ↗
3. 10.1038/s41578-019-0156-610.1038/s41578-019-0156-6 ↗
4. 10.1038/s41416-019-0704-210.1038/s41416-019-0704-2 ↗
5. 10.3390/pharmaceutics1404083410.3390/pharmaceutics14040834 ↗
6. 10.1016/j.ijpharm.2022.12155710.1016/j.ijpharm.2022.121557 ↗
7. Frequently Asked Questions, Bayer Aspirin. https://www.bayeraspirin.com/faqs/. (accessed March 7, 2024).
8. 10.1038/s41598-020-58801-110.1038/s41598-020-58801-1 ↗
9. 10.1126/sciadv.abm847810.1126/sciadv.abm8478 ↗
10. 10.1038/s41569-021-00629-x10.1038/s41569-021-00629-x ↗
11. 10.1055/a-1960-309210.1055/a-1960-3092 ↗
12. 10.7150/thno.1174210.7150/thno.11742 ↗
13. 10.1021/acs.molpharmaceut.0c0069410.1021/acs.molpharmaceut.0c00694 ↗
14. 10.21608/bfpc.2020.20253.106310.21608/bfpc.2020.20253.1063 ↗
15. 10.1007/s11051-009-9759-y10.1007/s11051-009-9759-y ↗
16. 10.1016/j.ejpb.2011.07.00510.1016/j.ejpb.2011.07.005 ↗
17. 10.1016/j.ijpharm.2014.03.04710.1016/j.ijpharm.2014.03.047 ↗
18. 10.3389/fmedt.2022.104005210.3389/fmedt.2022.1040052 ↗
19. 10.1080/17425247.2022.205147710.1080/17425247.2022.2051477 ↗
20. 10.2147/DDDT.S27361210.2147/DDDT.S273612 ↗
21. 10.1016/j.ijpharm.2019.11869710.1016/j.ijpharm.2019.118697 ↗
22. 10.1080/17425247.2018.144983210.1080/17425247.2018.1449832 ↗
23. 10.1111/jphp.1285210.1111/jphp.12852 ↗
24. 10.1080/21691401.2017.140812310.1080/21691401.2017.1408123 ↗
25. 10.4155/tde-2016-005510.4155/tde-2016-0055 ↗
26. 10.1016/j.jconrel.2015.03.03010.1016/j.jconrel.2015.03.030 ↗
27. 10.1021/ar200234q10.1021/ar200234q ↗
28. 10.3109/1061186090330281510.3109/10611860903302815 ↗
29. 10.1517/1742524090287040510.1517/17425240902870405 ↗
30. 10.2174/138920103348974810.2174/1389201033489748 ↗
31. 10.3390/pharmaceutics1408173210.3390/pharmaceutics14081732 ↗
32. 10.3390/pharmaceutics1211110010.3390/pharmaceutics12111100 ↗
33. 10.1021/acs.molpharmaceut.1c0007710.1021/acs.molpharmaceut.1c00077 ↗
34. 10.1016/j.jconrel.2022.02.00610.1016/j.jconrel.2022.02.006 ↗
35. 10.1016/j.nano.2020.10227710.1016/j.nano.2020.102277 ↗
36. 10.1016/j.ejps.2019.10501910.1016/j.ejps.2019.105019 ↗
37. 10.1016/j.bioadv.2023.21336810.1016/j.bioadv.2023.213368 ↗
38. 10.1038/s41565-020-0693-610.1038/s41565-020-0693-6 ↗
39. 10.1016/j.ijpharm.2020.11939210.1016/j.ijpharm.2020.119392 ↗
40. 10.1155/2021/997247510.1155/2021/9972475 ↗
41. 10.2147/IJN.S31917610.2147/IJN.S319176 ↗
42. 10.1016/j.ijpharm.2021.12120610.1016/j.ijpharm.2021.121206 ↗
43. 10.1016/j.msec.2020.11158210.1016/j.msec.2020.111582 ↗
44. Ghorban Dadras O. · J. Appl. Chem. Res. · 2015 · 9 · 21
45. Garces Garces, J.; Bonilla Munoz, A.; Parente Duena, A. Pharmaceutical preparation comprising coated capsules or tablets containing a liposome powder encapsulating a drug, EP 855179A2. 29–09–1998.
46. 10.1016/j.msec.2019.10980010.1016/j.msec.2019.109800 ↗
47. 10.1016/j.jddst.2018.12.01910.1016/j.jddst.2018.12.019 ↗
48. 10.1016/j.ijpharm.2020.11918510.1016/j.ijpharm.2020.119185 ↗
49. 10.1016/j.ijpharm.2020.11961510.1016/j.ijpharm.2020.119615 ↗
50. 10.1208/s12249-018-1237-310.1208/s12249-018-1237-3 ↗
51. 10.1093/jpp/rgab17610.1093/jpp/rgab176 ↗
52. 10.1208/s12249-020-01851-510.1208/s12249-020-01851-5 ↗
53. 10.4161/biom.1.1.1771710.4161/biom.1.1.17717 ↗
54. 10.3390/pharmaceutics1402043710.3390/pharmaceutics14020437 ↗
55. 10.4103/japtr.japtr_330_2110.4103/japtr.japtr_330_21 ↗
56. 10.3389/fbioe.2020.0031710.3389/fbioe.2020.00317 ↗
57. 10.1016/j.ijpharm.2019.11898210.1016/j.ijpharm.2019.118982 ↗
58. 10.1016/j.carbpol.2012.11.10510.1016/j.carbpol.2012.11.105 ↗
59. 10.3389/fbioe.2023.116729110.3389/fbioe.2023.1167291 ↗
60. 10.1002/adma.20200861810.1002/adma.202008618 ↗
61. 10.1016/j.jddst.2020.10221010.1016/j.jddst.2020.102210 ↗
62. 10.1016/j.carbpol.2015.05.06410.1016/j.carbpol.2015.05.064 ↗
63. 10.2147/DDDT.S8607510.2147/DDDT.S86075 ↗
64. 10.2147/IJN.S1790010.2147/IJN.S17900 ↗
65. 10.1016/j.jconrel.2022.10.05810.1016/j.jconrel.2022.10.058 ↗
66. 10.3389/fphar.2019.0105710.3389/fphar.2019.01057 ↗
67. 10.1016/j.ejpb.2010.11.02310.1016/j.ejpb.2010.11.023 ↗
68. 10.1002/jps.2468810.1002/jps.24688 ↗
69. 10.1016/j.ijpharm.2022.12200610.1016/j.ijpharm.2022.122006 ↗
70. 10.1097/MOG.0b013e328340076f10.1097/MOG.0b013e328340076f ↗
71. 10.1186/s13054-016-1434-y10.1186/s13054-016-1434-y ↗
72. 10.1002/adfm.20210499410.1002/adfm.202104994 ↗
73. 10.4014/jmb.1811.1102110.4014/jmb.1811.11021 ↗
74. 10.1007/s10570-016-0905-210.1007/s10570-016-0905-2 ↗
75. 10.3390/pharmaceutics1501029810.3390/pharmaceutics15010298 ↗
76. 10.1016/j.sbsr.2022.10052610.1016/j.sbsr.2022.100526 ↗
77. 10.1021/acsomega.1c0739310.1021/acsomega.1c07393 ↗
78. 10.1039/C6RA11799F10.1039/C6RA11799F ↗
79. 10.1016/j.ijpharm.2017.12.04910.1016/j.ijpharm.2017.12.049 ↗
80. 10.1016/j.ejpb.2014.06.00310.1016/j.ejpb.2014.06.003 ↗
81. 10.1021/acsnano.2c0795310.1021/acsnano.2c07953 ↗
82. 10.1016/j.ijpharm.2019.03.06410.1016/j.ijpharm.2019.03.064 ↗
83. 10.1016/j.apt.2018.05.00310.1016/j.apt.2018.05.003 ↗
84. 10.1016/j.ijpharm.2017.04.01210.1016/j.ijpharm.2017.04.012 ↗
85. 10.3109/03639045.2014.91452810.3109/03639045.2014.914528 ↗
86. 10.1016/j.ijpharm.2022.12171810.1016/j.ijpharm.2022.121718 ↗
87. 10.1021/acs.molpharmaceut.9b0119010.1021/acs.molpharmaceut.9b01190 ↗
88. 10.1080/10837450.2020.178549810.1080/10837450.2020.1785498 ↗
89. 10.1016/j.jddst.2022.10317210.1016/j.jddst.2022.103172 ↗
90. 10.1016/j.ejps.2022.10626310.1016/j.ejps.2022.106263 ↗
91. 10.1016/j.ijpharm.2022.12166010.1016/j.ijpharm.2022.121660 ↗
92. 10.1016/j.ijpharm.2014.06.01910.1016/j.ijpharm.2014.06.019 ↗
93. 10.1016/j.ijpharm.2018.06.06510.1016/j.ijpharm.2018.06.065 ↗
94. 10.1016/j.jddst.2019.10129810.1016/j.jddst.2019.101298 ↗
95. 10.3390/pharmaceutics1112065110.3390/pharmaceutics11120651 ↗
96. 10.1016/j.msec.2016.08.08310.1016/j.msec.2016.08.083 ↗
97. 10.1021/acsami.7b1652410.1021/acsami.7b16524 ↗
98. 10.1016/j.bioactmat.2022.12.02710.1016/j.bioactmat.2022.12.027 ↗
99. 10.1007/s40005-020-00495-810.1007/s40005-020-00495-8 ↗
100. 10.2147/DDDT.S28552210.2147/DDDT.S285522 ↗